Corcept Resubmits NDA for Relacorilant to Treat Cushing's Syndrome

Corcept Therapeutics resubmitted its New Drug Application to the FDA for relacorilant, incorporating additional data analyses requested by the agency, with an expected six-month review timeline. The resubmission is based on positive Phase III trial data showing the drug provides meaningful improvements in Cushing's syndrome symptoms with a favorable safety profile compared to existing treatments.